Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.32 |
| ▸ | GRK6 | P43250 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.31 |
| ▸ | CDK9 | P50750 | 2/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 2/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6294283 | 0.88 | FDPS (0.41) | MAPTMDM2 | |
| SCHEMBL7086522 | 0.82 | — | — | |
| SCHEMBL6289835 | 0.81 | — | — | |
| SCHEMBL6290700 | 0.76 | CA12 (0.36) | CCNT1CDK9GRM5 | |
| SCHEMBL27584131 | 0.74 | FDPS (0.43) | MAPTMDM2 | |
| SCHEMBL6291249 | 0.73 | CCNT1 (0.35) | CCNT1CDK9GRM5 | |
| SCHEMBL7164884 | 0.73 | FDPS (0.51) | MAPTMDM2 | |
| SCHEMBL6291102 | 0.70 | FDPS (0.42) | MAPTMDM2 | |
| SCHEMBL6291261 | 0.70 | ALPL (0.43) | MAPTMDM2 | |
| SCHEMBL6293877 | 0.69 | CCNT1 (0.34) | CCNT1CDK9GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6872711-B2 | β-substituted β-aminoethyl phosphonate derivatives | ILEX ONCOLOGY RESEARCH S.A. (CH) | 2005-03-29 | — | — | US | claimed |
| US-20020111488-A1 | Beta-substitued beta-aminoethyl phosphonate derivatives | ILEX PRODUCTS, INC. | 2002-08-15 | — | — | US | claimed |
| US-6872711-B2 | β-substituted β-aminoethyl phosphonate derivatives | ILEX ONCOLOGY RESEARCH S.A. (CH) | 2005-03-29 | — | — | US | disclosed |
| EP-1330463-A2 | BETA-SUBSTITUTED BETA-AMINOETHYL PHOSPHONATES | Ilex Oncology Research S.A. (CH) | 2003-07-30 | — | — | EP | disclosed |
| US-20020111488-A1 | Beta-substitued beta-aminoethyl phosphonate derivatives | ILEX PRODUCTS, INC. | 2002-08-15 | — | — | US | disclosed |
| WO-2002034756-A2 | BETA-SUBSTITUTED BETA-AMINOETHYL PHOSPHONATES | ILEX ONCOLOGY RESEARCH S.A. (CH) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111488-A1 | Beta-substitued beta-aminoethyl phosphonate derivatives | APOB, PHOSPHO1, APOL1 | MAPT 3652/4885NPSR1 1725/4885P4HTM 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.